Clinical Trial Update: Clinical Utility of CTC Test in Medicare-Eligible Metastatic Breast Cancer Patients

View source ↗

Summary

A clinical trial evaluating the utility of a circulating tumor cell (CTC) test in Medicare-eligible metastatic breast cancer patients has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: Janssen Diagnostics, LLC | Conditions: Metastatic Breast Cancer, Breast Cancer | Status: WITHDRAWN